Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2023 · 10-Q
Revenue$20.32M$20.32M+21.5% vs Q2 2022 Net Income-$2.19M-$2.19MN/M vs Q2 2022 EPS Diluted-$0.03-$0.03N/M vs Q2 2022 Gross Profit$12,356,000+23.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,280,000N/M Margins · derivedGross margin60.8%+0.8 pt vs Q2 2022
Operating margin-11.4%+26.8 pt vs Q2 2022
Net margin-10.8%+27.5 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end